AMP-activated protein kinase (AMPK) is a molecular energy sensor that acts to sustain cellular energy balance. Although AMPK is implicated in the regulation of a multitude of ATP-dependent cellular processes, exactly how these processes are controlled by AMPK as well as the identity of AMPK targets and pathways continues to evolve. Here we identify MAP kinaseinteracting serine/threonine protein kinase 1a (MNK1a) as a novel AMPK target. Specifically, we show AMPK-dependent Ser 353 phosphorylation of the human MNK1a isoform in cellfree and cellular systems. We show that AMPK and MNK1a physically interact and that in vivo MNK1a-Ser 353 phosphorylation requires T-loop phosphorylation, in good agreement with a recently proposed structural regulatory model of MNK1a. Our data suggest a physiological role for MNK1a-Ser 353 phosphorylation in regulation of the MNK1a kinase, which correlates with increased eIF4E phosphorylation in vitro and in vivo.
AMP-activated protein kinase (AMPK) is a molecular energy sensor that acts to sustain cellular energy balance. Although AMPK is implicated in the regulation of a multitude of ATP-dependent cellular processes, exactly how these processes are controlled by AMPK as well as the identity of AMPK targets and pathways continues to evolve. Here we identify MAP kinaseinteracting serine/threonine protein kinase 1a (MNK1a) as a novel AMPK target. Specifically, we show AMPK-dependent Ser 353 phosphorylation of the human MNK1a isoform in cellfree and cellular systems. We show that AMPK and MNK1a physically interact and that in vivo MNK1a-Ser 353 phosphorylation requires T-loop phosphorylation, in good agreement with a recently proposed structural regulatory model of MNK1a. Our data suggest a physiological role for MNK1a-Ser 353 phosphorylation in regulation of the MNK1a kinase, which correlates with increased eIF4E phosphorylation in vitro and in vivo.
Balancing catabolic and anabolic processes is fundamental to energy homeostasis and metabolic adaptation. The ␣␤␥ heterotrimeric AMP-activated protein kinase (AMPK) 3 promotes ATP production and limits ATP consumption (1, 2) . Shifts in the cellular AMP:ATP ratio are detected through the ␥ subunit, which cooperatively binds AMP. Consequential conformational changes within the heterotrimer stimulate AMPK kinase activity. Activation of AMPK further involves Thr 172 phosphorylation in the activation loop of the ␣ subunit kinase domain (3) . Additional (auto-) phosphorylation events are known to regulate AMPK (4 -6) . Through its established roles in lipid, glucose, and protein metabolism, AMPK functions at the crossroads of energy metabolism and basic cellular processes including cell proliferation, growth, and survival (7) (8) (9) . For example, AMPK-mediated regulation of acetyl CoA carboxylases ACC1 and ACC2 accelerates fatty acid synthesis and inhibits fatty acid oxidation, respectively (10) . AMPK is involved in control of cell growth via phosphorylation of regulatory-associated protein of mTOR (mechanistic target of rapamycin, Raptor) and tuberous sclerosis 2 (TSC2, tumor suppressor) (11, 12) .
Despite its well known role as energy sensor, a lack of knowledge on the identity of direct AMPK targets and thus of pathways involved in these processes persists. A substantial number of functional screening approaches have been developed to identify AMPK downstream targets and interaction partners (13) (14) (15) (16) (17) . High-density protein microarrays enable the rapid identification of potentially novel human kinase substrates at a proteomic scale (18) . Using this strategy, we identified MAP kinase-interacting serine/threonine protein kinase 1 (MNK1) as a putative novel AMPK target (19) . The human MKNK1 gene encodes two splice variants, MNK1a and MNK1b, which differ in their C-terminal sequences. In contrast to other MNKs, MNK1a has low basal activity and is highly induced upon activation (20) . MNK1a is activated by mitogen-and stress-activated protein kinases (M/SAPK), ERK (extracellular signalingregulated kinase), and P38, via phosphorylation of two threonine residues (Thr 209 and Thr 214 ) within the activation/ T-loop (21, 22) . MNK1 and MNK2 isoforms phosphorylate the eukaryotic translation initiation factor and mRNA cap-binding protein 4E (eIF4E) on serine 209 (23) (24) (25) . Although the exact biological relevance of this phosphorylation event is still under debate, cellular eIF4E plays an important role in the regulation of mRNA translation, in which interaction with the 5Ј-cap structure of mRNA appears pivotal (26) . Deregulation of eIF4E has been linked to tumorigenesis (26, 27) ; inhibition of protein translation, e.g. via MNK, is being considered for cancer treatment (20) .
Here we show that MNK1a is a genuine AMPK target in vitro and in vivo. MNK1a phosphorylation at Ser 353 by AMPK increases its kinase activity toward eIF4E phosphorylation. The relevance of our findings for human metabolic and neoplastic conditions is discussed.
Results

MNK1a Is a Novel AMPK Target in Vitro-
The online tool Scansite predicted the presence of a putative AMPK phosphorylation motif LQRNSSTMDL in MNK1a; this domain is absent in MNK1b. The putative AMPK target site in this motif, Ser 353 , is evolutionarily highly conserved among mammals and lower vertebrates (Fig. 1A) . To validate the initial phospho-protein microarray finding, cell-free in vitro kinase (IVK) assays were performed using recombinant AMPK and MNK1a. Mass spectrometric analysis of in vitro phosphorylated recombinant MNK1a
WT indicated Ser 353 as the primary phospho-site in the MNK1a-specific tryptic peptide sequence NSSTMDLTL-FAAEAIALNR (Ser 353 underlined; localization probability: 74%; Fig. 1A ). To further probe the specificity of this phosphoevent in vitro, the GST tag was also proteolytically removed from recombinant GST-MNK1a to exclude interference by GST tag phosphorylation (28) . Both GST-MNK1a
WT and MNK1a
WT protein were phosphorylated specifically and only in the presence of AMPK (Fig. 1B) . The absence of radiolabeled MNK1
WT protein in AMPK-free control reactions suggested that MNK1a
WT phosphorylation in vitro was AMPK-dependent and that MNK1a
WT protein did not show auto-phosphorylation under these conditions. A commercially available AMPK substrate antiserum, which detects a common AMPKphosphorylated LXRXXpS/pT motif, recognized in vitro phosphorylated MNK1a
WT , indicating that MNK1a phosphorylation occurred at an AMPK substrate-like motif (Fig. 1C) . The absence of detectable MNK1a
WT phosphorylation using a kinase-dead AMPK further corroborated the notion that MNK1 phosphorylation is dependent on the kinase activity of AMPK in vitro (Fig. 1D) (Fig. 1G) . The functional interaction between AMPK and MNK1a was studied in these cells using retrovirally expressed 2PY-MNK1a. Cells were treated with the AMPKactivating compound 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR); AMPK activity was assessed by pACC1 measurement. Although relatively low under control conditions (i.e. non-stimulated or serum-starved), AICAR dramatically increased 2PY-MNK1a
WT phosphorylation at an AMPK substrate-like motif (Fig. 1H) WT U2OS cells were glucose-deprived and AMPK and MNK1 phosphorylation was monitored. MNK1a-Ser(P) 353 and pACC1 were both induced upon glucose deprivation; both phosphorylation events correlated well with AMPK activation (Fig. 2C) . Relevantly, 1 h after replenishment of glucose, cells down-regulated MNK1-Ser(P) 353 and pACC1, in parallel with pAMPK (Fig. 2C) . These results are strongly suggestive of direct dynamic control of reversible MNK1a phosphorylation at Ser 353 by AMPK. AMPK activation aims to conserve cellular ATP by tuning energy-consuming processes such as mRNA translation to metabolic conditions. MNK1 is known to phosphorylate the eukaryotic initiation factor 4E (eIF4E) at Ser 209 , a rate-limiting component of the translation apparatus (31 phosphorylation, we studied specific MNK1a phospho-mutants in U2OS cells in combination with pharmacological stimulation rather than metabolic stress, as this allows separation of upstream signaling events. AICAR treatment, alone or in combination with TPA (M/SAPK activator), consistently and highly induced pACC1, whereas TPA treatment alone only modestly induced pACC1 (Fig. 2E ). TPA, with or without AICAR, massively increased MNK1-Thr(P) 209 / Thr(P) 214 (MNK1a-pTpT) (Fig. 2E) ; these observations are in good agreement with reported upstream signaling events connecting M/SAPKs to MNK1a (22) . Combination treatment with TPA and AICAR resulted in increased MNK1a-Ser(P) 353 (Fig. 2E) . As expected, the T209A/T214A (MNK1a T23A2 ) mutant was no longer phosphorylated at the mutated phospho-sites, and neither IP MNK1a T23A2 nor MNK1a K3M mutant kinases phosphorylated eIF4E (Fig. 2E) (Fig. 2E) . IP MNK1a
WT from AICAR only-treated cells led to only marginally increased peIF4E, in support of the need for regulatory co-signaling by M/SAPKs (Fig. 2E) . In contrast, and in good agreement with the observations above (cf. Fig. 2D ), MNK1a S353D consistently displayed enhanced peIF4E under AICAR only-or TPA only-treated conditions; moreover, eIF4E phosphorylation by MNK1a S353D was already enhanced under non-stimulated conditions (Fig. 2E) . Of note, pACC1 was not altered by MNK1a mutation. The combined data suggest that MNK1a selectively acts in the signaling downstream of AMPK, leading to increased eIF4E phosphorylation, and point toward a hierarchical order of regulatory events within MNK1a: M/SAPK-mediated MNK1a-Thr 209 / Thr 214 phosphorylation precedes AMPK-dependent MNK1a-Ser 353 phosphorylation.
Discussion
In this study, we report that MNK1a is a direct AMPK target. We provide biochemical and genetic evidence that MNK1a-Ser 353 is phosphorylated in vitro and in vivo in an AMPK-dependent manner and that AMPK and MNK1a physically interact. Finally, we show that MNK1a-Ser(P) 353 correlates with increased eIF4E phosphorylation in vitro and in vivo.
Members of the MAPK-activated protein kinase (MK) family fulfill multiple biological roles in cellular responses to extracellular cues (e.g. mitogenic stimulation and cellular stress). MNK1a, like other MAPKAPKs (MAP kinase-activated protein kinases), is tightly regulated by M/SAPKs, including ERK and P38 (32, 33) . The most well characterized biochemical connection in regard to MNK1 is eIF4E-Ser 209 phosphorylation (24) , although the exact relevance of MNK1-mediated eIF4E phosphorylation remains unclear (34) . MNK1a mutation appears to affect phosphorylation of eIF4E, not of ACC1, suggesting a selective role for MNK1a as a signaling intermediate in the regulation of protein synthesis, downstream of AMPK.
Based on a previously proposed regulatory model of MNK1a, our data suggest a physiological role for Ser 353 phosphorylation in regulating MNK1a activity. MNK1a is activated upon T-loop phosphorylation, but also undergoes a conformational change to a more "open" structure (21) . Our MNK1a mutant analysis indicating that Thr 209 /Thr 214 phosphorylation is a prerequisite for Ser 353 phosphorylation appears congruent with this phosphoevent being dependent on conformational change. Interestingly, an ␣ helical structure from the first part of the unique MNK1a . C, IVK assays as in B, using "cold" ATP instead. Protease-mediated removal of the GST tag was performed as indicated in the figure. Immunoblot (IB) detection of phosphorylated MNK1a using phosphorylated AMPK substrate (AMPK-sub) antiserum or antiserum against total Mnk1 protein (tMNK1) is shown. D, as in C. IVK analyses include: active (WT), kinase-dead (KD), or no AMPK. IB detection was done using the indicated antisera. E, IVK. Purified recombinant GST-MNK1a
WT and mutant GST-MNK1a S353A or GST-MNK1a S352A proteins were incubated with active AMPK and [␥-32 P]ATP. Upper panel, pMNK1a autoradiograph. Lower panel, CBB image (used as loading control). F, as in C. IVK analyses were performed with cold ATP. IB detection was done using the indicated antisera. G, MNK1a and AMPK protein levels in HeLa cervical adenocarcinoma, U2OS, MEF, TIG3 human primary fibroblasts, HEK293T human embryonic kidney, and HL-1 immortal murine cardiomyocytes. IB analyses of total cell extracts using the indicated antisera were performed. H, U2OS cells expressing 2PY-MNK1a
WT or MNK1a S353A (control: empty vector (ev)) were treated as indicated (c: control conditions; ss: serum-starved; AI: ssϩAICAR). MNK1a was IP using PY antiserum; IB analysis of immunoprecipitation and input material was performed using the indicated antisera. I, as in C. IVK analyses using purified recombinant GST-MNK1a
WT protein, active AMPK, and cold ATP were performed. Protease-mediated removal of the GST tag was performed as indicated in the figure. IB of phosphorylated MNK1a were performed using the indicated antisera. J, as in H. IVK analyses using purified GST-MNK1a
WT or GST-MNK1a S353A with active AMPK and cold ATP were performed. IB was done using the indicated antisera. K, U2OS cells expressing 2PY-MNK1a
WT , 2PY-MNK1a S353A , or transduced with empty vector (ev) were treated as indicated (serum-starved (ss) or ssϩAICAR (AI)).
C-terminal region was predicted to suppress basal T-loop phosphorylation and activity (21); Ser
353 is located at the start of this region. Based on existing and current data, we propose a functional extension to the MNK1a activation model: T-loop phosphorylation by canonical M/SAPK pathway activity precedes AMPK-mediated phosphorylation of MNK1a at Ser 353 (Fig. 2F ). Our observations suggest that MNK1a-Ser 353 phosphorylation by AMPK is not required for MNK1a activation per se, but affects and/or possibly directs kinase activity, upon a conformational change induced by M/SAPK. MNK1-Ser(P) 353 may serve to fine-tune MNK1-eIF4E-mediated protein synthesis (mRNA translation) via AMPK. This finding has potential therapeutic implications for chronic or acute human conditions, including metabolic syndrome-associated disorders and cancer. Abnormal regulation of protein synthesis is known to drive tumor cell proliferation and survival. Importantly, both AMPK and MNK1a have been independently put forward as potential druggable targets (35, 36) .
Experimental Procedures
Expression Vectors-For bacterial expression of MNK1a protein, glutathione S-transferase(GST)-tagged MNK1a (pGEX-6P1) was kindly provided by C. G. Proud (Southampton, UK) (21) . Active, hexahistidine-tagged (His 6 ) AMPK was produced using a single hexacistronic expression vector encoding three AMPK and three LKB1 subunits as described (5) . Expression of kinase-dead AMPK␣1 D157A mutant was described earlier (37) . Point mutations were introduced using QuikChange (Agilent). To generate eukaryotic expression vector, MNK1a cDNAs were subcloned in-frame with an N-terminal double polyoma (2PY) tag into the BamHI and SalI sites of a retroviral pBabe vector (38) . Amphotropic retrovirus was produced as described (39) ; transduced U2OS and MEF cells were selected in medium containing 4 g/ml puromycin.
Recombinant Protein Purification and Cell-free Kinase Assays-Proteins were expressed in Rosetta 2 (DE3) Escherichia coli cells (Merck Millipore) as described (5). His 6 -AMPK and GST-MNK1a protein were purified using nickel-Sepharose HP (GE Healthcare) and glutathione-Sepharose 4B (GE Healthcare), respectively. AMPK protein was eluted in elution buffer (50 mM NaH 2 PO 4 , 30% glycerol, 0.5 M sucrose, 250 mM imidazole, pH 8) MNK1a protein was eluted with freshly prepared buffer (50 mM Tris-HCl, 10 mM reduced glutathione, pH 8).
Aliquots of resin-bound MNK1a protein (10 g) were incubated in 50 l of kinase buffer (50 mM Hepes, pH 7.4, 5 mM MgCl 2 , 0.04 mM AMP, 1 mM DTT, 200 M ATP) with 1 g of active AMPK protein and 4 Ci of [␥-32 P]ATP for 15 min at 37°C. Beads were collected by centrifugation (5 min, 800 ϫ g), washed, and suspended in cleavage buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 1 mM DTT). For proteolytic removal of GST tags, resin-bound protein was incubated with PreScission protease (GE Healthcare) for 4 h at 4°C with constant mixing. Beads were pelleted (5 min, 800 ϫ g); supernatant was transferred to a fresh tube. Samples were heated in SDS-PAGE sample buffer (5 min, 95°C). Samples were analyzed by SDS-PAGE (9% gels) electrophoresis followed by Coomassie Brilliant Blue (CBB) staining and/or autoradiography.
Mass Spectrometry-GST-MNK1a and AMPK proteins were incubated with or without ATP in vitro as described above. Samples were separated by SDS-PAGE; MNK1a bands were excised and in-gel digested as described (40) . Extracted tryptic peptides were desalted using homemade C18 columns, resuspended in 10% formic acid, and analyzed by reversed phase nanoLC-MS/MS (Ultimate 3000 and Orbitrap Elite; Thermo Scientific). Peptides were trapped on a precolumn for 10 min (Acclaim PepMap100, C18, 5 m, 100 Å, 300-m inner diameter ϫ 5 mm, Thermo Scientific) in Buffer A (0.1% formic acid in water) and separated on an analytical column (Acclaim PepMap100, C18, 5 m, 100 Å, 75-m inner diameter ϫ 25 cm) using a 70-min gradient (0 -10 min, 5% buffer B (80% acetonitrile, 0.1% formic acid); 10 -45 min, 10 -45% buffer B; 45-47 min, 45-99% buffer B; 47-53 min, 99% buffer B; 53-70 min, 5% buffer B) at 250 nl/min. The mass spectrometer was operated in data-dependent mode with a 20-s dynamic exclusion range. Full-scan MS spectra were acquired in the Orbitrap (range: m/z 350 -1500) with a resolution of 120,000 and an automatic gain control of 1E6 ions. Collision-induced dissociation fragmentation in the ion trap was performed on the top five precursors of each full scan employing a collision energy of 35%. Analysis of raw data was done by using MaxQuant (version 1.4.1.2 (41)). The spectra were searched against the human Swiss-Prot database version 06/2014 using the Andromeda search engine using default mass tolerance settings (42) . Trypsin was set as the protease (two missed cleavages allowed). Fixed modification: carbamidomethylation (Cys); variable modifications: oxidation (Met), phosphorylation (Ser, Thr, Tyr), and N-terminal protein acetylation. False discovery rate was set to 0.01 for peptides, proteins, and modification sites. The minimum peptide score for modified peptides was set to 40, and the minimum peptide length was seven amino acids (aa).
Cell Culture, Chemicals, and Antibodies-Human osteosarcoma U2OS cells and immortal mouse embryo fibroblasts (AMPK WT and AMPK dKO MEFs (43)) were cultured in DMEM (25 mM glucose; Gibco), supplemented with 10% (v/v) heatinactivated fetal calf serum (Bodinco BV, Alkmaar, The Neth- WT were treated with AICAR or A769662 as indicated. IB analyses of total cell extracts using the indicated antisera were performed. B, U2OS cells expressing 2PY-MNK1a WT (control: empty vector, ev), were treated as indicated: c, control conditions, serum-starved (ss), ssϩAICAR (AI) (cf. Fig. 1G ), or glucose-deprived (GD)). IB analyses of immunoprecipitation and input material using the indicated antisera were performed; bACT, loading control. C, U2OS cells expressing 2PY-MNK1a
WT were glucose-deprived (GD, indicated in hours). #, cells were glucose-deprived, and glucose was re-administered for 1 h. Immunoprecipitation and Immunoblotting-Cells were lysed in mild lysis buffer (250 mM NaCl, 0.1% IGEPAL (Nonidet P-40), 5 mM EDTA, 50 mM HEPES, pH 7.0) supplemented with 5 mM benzamidine, 5 g/ml antipain, 5 g/ml leupeptin, 5 g/ml aprotinin, 1 mM sodium vanadate, 10 mM sodium fluoride, 10 mM pyrophosphate, 10 mM ␤-glycerophosphate, 0.5 mM DTT, and 1 mM PMSF. Extracts were sonicated on ice and centrifuged; 3% of the supernatant was stored as input (Ϫ80°C). Endogenous AMPK was IP using a mix of AMPK␣1 and AMPK␣2 antibodies (sheep polyclonal; kindly provided by D. G. Hardie, Dundee, Scotland, UK); 2PY-tagged MNK1a (2PY-MNK1a) was IP using PY antiserum (Covance). For immunoprecipitation, 500 g of protein lysate were incubated with primary antibody under constant mixing at 4°C overnight, followed by incubation with protein G-Sepharose beads (4 h, 4°C). Immune complexes were collected by centrifugation and analyzed by immunoblotting as described (5) . Signals were detected using enhanced chemiluminescence (ECL; Pierce). Band intensities were quantitated with the Quantity One software (Bio-Rad). Data were statistically analyzed by performing two-tailed paired t tests using Microsoft Excel.
eIF4E Kinase Assay-350 g of U2OS 2PY-MNK1a cell lysates were incubated with PY antibody (2 h, 4°C); 40 l of protein G slurry were added for 1.5 h (4°C). Beads were pelleted (5 min, 800 ϫ g) and washed twice with mild lysis buffer, twice with 0.5 M LiCl, and twice with kinase buffer as described previously (21) . Beads were re-suspended in 50 l of kinase buffer and incubated (15 min, 37°C) with 1 g of recombinant GST-eIF4E. The reaction was terminated by adding SDS-PAGE sample buffer (5 min, 95°C). Samples were analyzed by SDS-PAGE (9% gels) and autoradiography. 200 g of cell lysates were processed in parallel with immunoprecipitation antibody as controls.
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